Novel Therapies in Prostate Cancer
For advanced prostate cancer, novel biomarker-driven therapies include olaparib for BRCA1/2-altered mCRPC, lutetium-177-PSMA-617 for PSMA-positive disease after ARPI and docetaxel, and pembrolizumab for MSI-H/dMMR tumors, with treatment selection critically dependent on molecular testing performed early in the disease course.
Biomarker Testing: The Foundation
Early molecular profiling is mandatory before initiating mCRPC treatment 1. Test for:
- Homologous recombination repair (HRR) gene alterations (BRCA1, BRCA2, ATM and others)
- Microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR)
- PSMA expression via PET imaging when considering radioligand therapy
The survival benefit from targeted therapies depends entirely on identifying the right biomarker at the right time—delaying testing means missing therapeutic windows 1.
HRR-Altered Disease: PARP Inhibitors
BRCA1/2 Alterations (Strongest Evidence)
Olaparib should be considered after ARPI therapy (with or without prior taxane) for patients with mCRPC and BRCA1/2 alterations 2. The PROfound trial demonstrated:
- Overall survival improvement: HR 0.69 (95% CI 0.50-0.97, P=0.0175)
- Median OS: 19.1 vs 14.7 months 2
- Benefit predominantly in BRCA-altered patients, not non-BRCA HRR alterations 2
Critical Nuance on Combination vs Sequential Therapy
The BRCAAway study showed concurrent olaparib + abiraterone significantly better than sequential use in BRCA1/2 or ATM-mutated patients 1. This means:
- First-line mCRPC with BRCA1/2 alterations: Consider PARP inhibitor + ARPI combination upfront
- Post-ARPI progression: Olaparib monotherapy remains effective but combination would have been superior
Common pitfall: Non-BRCA HRR alterations (ATM, PALB2, etc.) show heterogeneous and often limited benefit—do not assume all HRR mutations respond equally 3.
PSMA-Positive Disease: Radioligand Therapy
Post-ARPI and Post-Docetaxel Setting
177Lu-PSMA-617 is recommended (Level I, A) for mCRPC patients with PSMA-expressing tumors on PET imaging, without PSMA non-expressing lesions, after progression on ARPI and taxane 2.
The VISION trial demonstrated:
- Radiographic PFS: HR 0.40 (medians 8.7 vs 3.4 months)
- Overall survival: HR 0.62 (medians 15.3 vs 11.3 months) 2
- ESMO-MCBS score: 4 (highest clinical benefit) 2
Earlier-Line Use: Emerging Evidence
The PSMAfore study showed 177Lu-PSMA-617 vs alternate ARPI (before chemotherapy):
- Median rPFS: 11.60 vs 5.59 months, HR 0.49 1
- No OS difference at analysis (51% crossover confounds interpretation)
Practical selection criteria 4:
- PSMA PET uptake intensity and homogeneity (heterogeneous uptake predicts poor response)
- Absence of liver metastases (associated with worse outcomes)
- Adequate bone marrow reserve (prior extensive chemotherapy limits tolerability)
- Renal function (radioligand excretion considerations)
Critical caveat: PSMA-negative lesions on PET imaging predict resistance—these patients should not receive radioligand therapy 2.
MSI-H/dMMR Disease: Immunotherapy
Pembrolizumab is recommended for mCRPC with MSI-H or dMMR status 1. While less common in prostate cancer (~3-5% of mCRPC), these tumors show durable responses to immune checkpoint inhibition.
Testing strategy: Perform MSI/dMMR testing on tumor tissue early, as this biomarker guides a completely different therapeutic mechanism 1, 5.
Treatment Sequencing Algorithm
For Newly Diagnosed mCRPC (Post-mHSPC Progression)
Step 1: Molecular testing immediately
- HRR panel (germline + somatic)
- MSI-H/dMMR status
- PSMA PET if considering radioligand therapy
Step 2: Treatment selection based on biomarkers and prior therapy
If BRCA1/2-altered:
- Not previously on ARPI: Olaparib + abiraterone combination (preferred based on BRCAAway) 1
- Post-ARPI progression: Olaparib monotherapy 2
If PSMA-positive and post-ARPI + docetaxel:
- 177Lu-PSMA-617 (Level I, A recommendation) 2
- Ensure no PSMA-negative lesions on imaging
If MSI-H/dMMR:
- Pembrolizumab 1
If no actionable biomarker:
- Post-ARPI only: Docetaxel (if not used in mHSPC) or cabazitaxel
- Post-ARPI + docetaxel: Cabazitaxel or 177Lu-PSMA-617 (if PSMA-positive) 2
Critical Sequencing Principle
Avoid ARPI-to-ARPI switching—the CARD trial showed cabazitaxel superior to second ARPI (enzalutamide/abiraterone) post-progression:
Common Pitfalls to Avoid
Delaying molecular testing until multiple lines of therapy: HRR and MSI-H testing should occur at mCRPC diagnosis, not after exhausting options 1
Assuming all HRR mutations benefit equally from PARP inhibitors: BRCA1/2 show robust benefit; non-BRCA HRR alterations are heterogeneous 2, 3
Using 177Lu-PSMA-617 without proper imaging selection: PSMA-negative lesions predict resistance—PET imaging is mandatory 2, 4
Sequential ARPI use: Abiraterone→enzalutamide or vice versa shows limited benefit; switch mechanisms instead 1
Ignoring bone marrow reserve before radioligand therapy: Prior extensive chemotherapy or bone metastases may limit tolerability 4, 6
Emerging Therapies on the Horizon
While not yet standard, bispecific T-cell engagers, antibody-drug conjugates, and androgen receptor degraders are in clinical trials and may expand options beyond current mechanisms 7, 8, 9. These represent the next wave of biomarker-driven precision oncology in prostate cancer.